The five-star Langham Hotel in central London hosted the third annual SIP Global Health Conference on longevity, attracting around 150 attendees on Wednesday to discuss emerging approaches to extending human life. The event, organised by the SIP Medical Family Office, a Swiss firm specialising in health management and international medical insurance, focused on cutting-edge medical treatments, disease prevention, and the impact of external factors such as climate change and technology on ageing.
The conference drew primarily Harley Street doctors, lawyers, and wealth managers, many representing high-net-worth individuals who are increasingly investing in longevity interventions. According to an executive from AXA Global Healthcare, approximately 85% of wealthy individuals in the UK are already engaged in such treatments. A wealth management expert noted a marked migration of millionaires away from the UK, citing better healthcare prospects as a key reason, with the UAE identified as a leading destination for this demographic.
Experts highlighted a wide spectrum of challenges to healthy ageing. Dr Andrew Renshaw, a fellow of the Royal Society of Public Health and regional medical director for International SOS, underscored the growing threats posed by obesity, artificial intelligence, and climate change. He warned that global warming was expanding the range of infectious diseases, such as malaria, dengue fever, chikungunya, and West Nile virus, beyond their traditional zones, now appearing in areas including parts of the United States and southern Europe. Renshaw referenced recent concerns about hantavirus outbreaks on luxury yachts as an example of health risks associated with changing environments.
On a more hopeful note, Dr Paul Jarman, chairman of neurology at Cleveland Clinic London, highlighted advances in early Alzheimer’s detection and treatment. He described a blood test called P-Tau217 capable of identifying the disease in patients with mild cognitive symptoms. Jarman noted that although new drugs that can slow Alzheimer’s progression exist, they are costly and not yet available through the National Health Service. He also discussed ongoing clinical trials aimed at preventing the onset of Alzheimer’s in asymptomatic individuals, with results expected around 2028.
A session on stem cell therapies reflected interests popular in Silicon Valley biohacking circles. Dr Todd McAllister, an American biochemist, and Dr Nadir Kadri, an immunologist from Sweden, presented stem cell injections as a promising preventive strategy. Kadri explained that these treatments “instruct the immune system” to repair bodily damage, citing trials in the UAE targeting severe inflammation linked to frailty. Both scientists noted the expansion of stem cell clinics globally, including in Dubai, Florida, Istanbul, and London. Currently costing about £18,000 per treatment, they suggested prices could fall with increased demand and production, potentially allowing healthy individuals to use stem cells proactively to delay ageing-related illnesses.
The conference underscored longevity’s growing prominence among the global elite and medical community, highlighting both emerging scientific advances and persistent uncertainties in the quest to extend human healthspan amidst evolving environmental and technological challenges.